UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-12111 Pediatrix Medical Group, Inc. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or othe ...

Pediatrix Medical Group, Inc. (NYSE:MD) Q4 2022 Earnings Conference Call February 17, 2023 9:00 AM ET Company Participants Charles Lynch ??? Senior Vice President, Finance and Strategy Mark Ordan ??? Executive Chair Jim Swift ??? Chief Executive Officer Marc Richards ??? Chief Financial Officer Conference Call Participants Jack Senft ??? William Blair AJ Rice ??? Credit Suisse Pito Chickering ??? Deutsche Bank Whit Mayo ??? SVB Securities Kevin Fischbeck ??? Bank of America Rishi Parekh ??? JPMorgan Tao Qi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Registrant's telephone number, including area code (954) 384-0175 Securities registered pursuant to Section 12(b) of the Act: | Title of Each Class | Trading Symbol | Name of Each Excha ...

Pediatrix Medical Group, Inc. (NYSE:MD) Q3 2022 Earnings Conference Call November 3, 2022 9:00 AM ET Corporate Participants Charles Lynch - Investor Relations Mark Ordan - Chief Executive Officer Marc Richards - Chief Financial Officer James Swift - Chief Operating Officer Conference Call Participants Pito Chickering - Deutsche Bank Whit Mayo - SVB Securities Tao Qiu - Stifel Kevin Fischbeck - Bank of America Brian Tanquilut - Jefferies AJ Rice - Credit Suisse Operator Ladies and gentlemen, thank you for st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number: 001-12111 Pediatrix Medical Group, Inc. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or other jurisdiction of Incorporation or organization) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Pediatrix Medical Group, Inc. (NYSE:MD) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Corporate Participants Charles Lynch - Investor Relations Mark Ordan - Chief Executive Officer Marc Richards - Chief Financial Officer Conference Call Participants Tao Qiu - Stifel Brian Tanquilut - Jefferies Kevin Fischbeck - Bank of America Pito Chickering - Deutsche Bank Whit Mayo - SVB Securities Ryan Daniels - William Blair AJ Rice - Credit Suisse Operator Ladies and gentlemen, thank you for standing by, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-12111 Pediatrix Medical Group, Inc. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or other ...

MEDNAX, Inc. (NYSE:MD) Q1 2022 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Charles Lynch - SVP, Finance, Strategy & IR Mark Ordan - CEO & Director Marc Richards - EVP & CFO James Swift - Chief Development Officer Conference Call Participants Tao Qiu - Stifel, Nicolaus & Company A.J. Rice - Cr??dit Suisse Nicholas Spiekhout - William Blair & Company Whit Mayo - SVB Leerink Kevin Fischbeck - Bank of America Merrill Lynch Operator Ladies and gentlemen, thank you for standing by, and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from ______ to ______ Commission File Number: 001-12111 Mednax, Inc. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or other jurisdiction of Incorporation or organization) 1301 Concord Terrace Sunrise, Florida 33323 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION RE ...

Financial Data and Key Metrics Changes - The fourth quarter results were in line with expectations, reflecting a strong recovery from the previous year, with total births at hospitals providing NICU services up 5% and NICU days up 5.6% on a same-unit basis [5][6] - The company recorded significant funds from the CARES Act, totaling $26 million in revenue and $16.5 million in adjusted EBITDA for the quarter [8][9] - The outlook for 2022 includes expected revenue of approximately $2 billion and adjusted EBITDA of at least $270 million, with a focus on efficiency improvements [8][16] Business Line Data and Key Metrics Changes - The company achieved solid results in 2021 compared to pre-pandemic levels, with same-unit volumes growing by roughly 1% despite a 2.5% decline in the first quarter of the previous year [6][8] - The transition of revenue cycle operations to R1 is expected to yield meaningful savings, which began to be seen in Q3 of the previous year [7][9] Market Data and Key Metrics Changes - The payer mix was favorable year-over-year, reflecting a slightly favorable comparison to pre-pandemic levels [5] - The company is focused on expanding its pediatric primary and urgent care clinics, with recent acquisitions in Houston and Orlando [10][11] Company Strategy and Development Direction - The company is transitioning to operate under a unified Pediatrix brand, which is expected to strengthen existing relationships and open new opportunities [12][13] - The company is committed to environmental, social, and governance (ESG) goals, having improved its average ISS ESG quality score from over six to three [14] Management's Comments on Operating Environment and Future Outlook - Management noted that the impact of surprise billing legislation is currently limited due to a strong payer relationship and a diversified contract portfolio [15] - The company has not experienced significant workforce pressures or turnover, although the recruiting environment remains challenging [32] Other Important Information - The refinancing of the capital structure is expected to reduce annual debt service expenses by more than half and lower the weighted average interest rate on borrowings from 6.25% to under 4% [18][19] - The company is evaluating several markets for new clinic openings, with plans to open new clinics before the end of the year [45] Q&A Session Summary Question: Initial evidence from payers regarding surprise billing regulation - Management indicated a mix of responses from payers, with some contracts being renewed at higher rates while others are waiting to see how the situation develops [24] Question: Impact of supply chain issues - Management stated that they are not assuming any impact from surprise billing in their numbers, but expect modifications to the IFR based on feedback received [29] Question: Workforce pressures and inflation - Management reported no material workforce pressures so far, although they acknowledge the tough recruiting environment [32] Question: Update on Brave Care acquisition integration - Integration of Brave Care's technology into existing platforms is ongoing and expected to enhance patient experience in clinics [34] Question: Accounts receivable increase and CMS guidance on newborn screenings - Management explained that the increase in accounts receivable was expected due to the transition of the RCM function, and the impact from CMS changes on newborn screenings was noted but not significant to overall revenue [38][40] Question: G&A guidance and savings opportunities - Management discussed ongoing efforts to streamline operations and the potential for future savings from the RCM outsourcing initiative [42][43]